Apparently Paul is participating in a Chinese conference and the company gets more coverage from China, deals get done globally...
“First, the peptides have a smaller molecular weight, which makes PDCs have better affinity, specificity and tissue permeability, and are useful in the treatment of certain solid tumors. In terms of curative effect, secondly, peptides have low immunogenicity, can be quickly eliminated by the kidney, and have better safety; thirdly, the design of PDC molecule is relatively simple, which is expected to break through the limitations of ADC due to complex structure and high production cost.
Recently, another biomedical company called Theratechnologies also announced the research progress of two PDCs in its R&D pipeline. Among them, TH1902 is a PDC with docetaxel as the payload, which is planned to be developed to treat triple-negative breast and ovarian cancer. The other TH1904 uses doxorubicin as a payload and is intended to be developed to treat ovarian cancer. Both PDCs target neurotensin receptor 3 (SORT1, also known as NTSR3). SORT1 has been confirmed to be expressed in a variety of cancers, including triple-negative breast cancer, ovarian cancer, lung cancer, and colorectal. Cancer, skin cancer, pancreatic cancer, etc.
According to the official information of Theratechnologies company, compared with traditional chemotherapy, TH1902 and TH1904 can selectively deliver anti-cancer active ingredients to SORT1 in cancer cells, and the anti-cancer active ingredients are quickly internalized and released by cancer cells. Pre-clinical studies have shown that TH1902, which combines a peptide targeting SORT1 receptor, a linker, and docetaxel, has better anti-metastatic activity and better tolerance than docetaxel alone.”
https://med.sina.cn/article_detail_103_2_105300.html